Similar articles for PMID: 23572497

Year	Number of Results
1984	1
1990	1
1998	1
2002	1
2004	2
2005	2
2006	4
2007	7
2008	3
2009	13
2010	9
2011	18
2012	27
2013	23
2014	38
2015	27
2016	36
2017	26
2018	32
2019	30
2020	25
2021	26
2022	18
2023	8
2024	0

1

Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Nielsen D, Jensen BV, Hendel HW. Skougaard K, et al. J Nucl Med. 2013 Jul;54(7):1026-31. doi: 10.2967/jnumed.112.111757. Epub 2013 Apr 9. J Nucl Med. 2013. PMID: 23572497 Free article. Clinical Trial.

2

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Johannesen HH, Nielsen D, Schou JV, Jensen BV, Høgdall EV, Hendel HW. Skougaard K, et al. Cancer Med. 2014 Oct;3(5):1294-301. doi: 10.1002/cam4.271. Epub 2014 Jun 18. Cancer Med. 2014. PMID: 24941936 Free PMC article.

3

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Nielsen D, Jensen BV, Pfeiffer P, Hendel HW. Skougaard K, et al. Acta Oncol. 2016 Sep-Oct;55(9-10):1175-1182. doi: 10.3109/0284186X.2016.1170197. Epub 2016 Aug 22. Acta Oncol. 2016. PMID: 27548393 Clinical Trial.

4

Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.

Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H. Shang J, et al. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1945-53. doi: 10.1007/s00259-016-3420-7. Epub 2016 May 28. Eur J Nucl Med Mol Imaging. 2016. PMID: 27236466 Clinical Trial.

5

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.

Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A. Depardon E, et al. PLoS One. 2018 Jul 16;13(7):e0199529. doi: 10.1371/journal.pone.0199529. eCollection 2018. PLoS One. 2018. PMID: 30011328 Free PMC article.

6

The utility of ⁶⁸F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.

Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K. Kitajima K, et al. Hell J Nucl Med. 2021 Sep-Dec;24(3):186-198. doi: 10.1967/s002449912402. Epub 2021 Dec 17. Hell J Nucl Med. 2021. PMID: 34901959 Free article.

7

TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.

Ho KC, Fang YD, Chung HW, Liu YC, Chang JW, Hou MM, Yang CT, Cheng NM, Su TP, Yen TC. Ho KC, et al. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2155-2165. doi: 10.1007/s00259-016-3433-2. Epub 2016 Jun 3. Eur J Nucl Med Mol Imaging. 2016. PMID: 27260520

8

Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).

Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J. Fledelius J, et al. J Med Imaging Radiat Oncol. 2016 Apr;60(2):231-8. doi: 10.1111/1754-9485.12427. Epub 2015 Dec 18. J Med Imaging Radiat Oncol. 2016. PMID: 26678718

9

Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.

Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, Monteil J. Ziai D, et al. Cancer Imaging. 2013 Mar 5;13(1):73-80. doi: 10.1102/1470-7330.2013.0008. Cancer Imaging. 2013. PMID: 23466871 Free PMC article.

10

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.

Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96. doi: 10.1007/s00259-014-2944-y. Epub 2014 Oct 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 25359635

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

318 results

Results by year